Clinical trial
A Phase Ib/II, Efficacy and Safety Study of NTB003 in Participants With Thyroid Eye Disease (TED)
NCT07462130 is registered in ClinicalTrials.gov with Nanjing Chia-tai Tianqing Pharmaceutical as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase Ib/II, Efficacy and Safety Study of NTB003 in Participants With Thyroid Eye Disease (TED)
- Lead sponsor
- Nanjing Chia-tai Tianqing Pharmaceutical
- Phase
- Phase 1/2
- Overall status
- Not yet recruiting
- Start date
- March 1, 2026
- Completion date
- March 30, 2028
- Enrollment
- 74 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.
thyroid eye disease